CLINICAL_TRIALS
trial_result
· 2025-12-30
Clinical Trial Update: A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age [Phase 3]
Summary
Phase 3 results for Moderna's RSV vaccine candidate mRNA-1345 in adults aged 50 and older have been posted after study completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: ModernaTX, Inc. | Conditions: Respiratory Syncytial Virus | Phase 3 | Status: COMPLETED | Results posted: 2025-12-30